Compare Omnicom Group Inc. (OMC) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Omnicom Group Inc. vs ResMed Inc. — how do they compare? Omnicom Group Inc. trades at $79.2 (market cap $22.58B), while ResMed Inc. trades at $193.21 (market cap $28.40B). The key difference: ResMed Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays the higher dividend (4.04%). Which is the better fit depends on your goals.
| OMC | RMD | |
|---|---|---|
Market Cap | $22.58B | $28.40B |
Sector | Media | Health |
52-Week High | $85.80 | $293.73 |
52-Week Low | $67.27 | $182.82 |
Enterprise Value | $29.80B | $27.58B |
Dividend Yield | 4.04% | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Omnicom Group (OMC) trades at $79.21, down 3.08% today, with a bullish technical signal from moving averages. The company reported mixed Q1 2026 earnings, beating expectations with $1.90 EPS versus $1.82 expected, but Q4 2025 missed at $2.59 versus $2.72. Revenue growth is strong, reaching $17.27 billion in 2025, though net income was negative $54.50 million due to elevated taxes. Analyst consensus is mixed with 32% buy ratings and a $105.75 price target, representing significant upside. Recent news highlights major client wins including IBM's global media account and partnerships with Netflix and Disney.
OMC presents a value opportunity with a low P/E of 12.16 and P/S of 0.96, trading below analyst targets. The advertising holding company benefits from AI platform expansion and strategic partnerships, but faces margin pressure and intense competition. Near-term catalysts include Q2 2026 earnings on July 28, 2026, where the company must deliver on the expected $2.58 EPS to maintain investor confidence amid current bearish sentiment.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
